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1. Introduction  
Unfortunately, most of the common diseases in cardiology do not show traditional 
Mendelian genetics, they usually are complex genetic diseases resulting from the 
combination of multiple heritable and environmental factors. However, one of the 
cardiology dysfunction that can affect apparently healthy young adults or with any 
previous heart disease, such as sudden cardiac death (SCD), could be the first symptom of a 
Mendelian disease such as cardiomyopathies or channelopathies. 
In many of the SCD cases, especially in case of young people, the cause of death cannot be 
explained neither after autopsy nor after laboratory tests. Inherited heart diseases such as 
hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy 
(ARVC) and primary electrical diseases such as long QT syndrome (LQTS), Brugada 
syndrome (BrS) or catecholaminergic polymorphic ventricular tachycardia (CPVT), are the 
main cause of death in young adults with no previous clinical history. Most often these 
inherited cardiac disorders give rise to lethal ventricular arrhythmias and show an 
autosomal dominant mode of inheritance. 
Genetic screening of the genes described as implicated in the different pathologies may help 
to determine the cause of death and to evaluate the potential risk of the relatives. Today we 
know which are the main causes of sudden cardiac death in young adults and we also know 
which are the genes responsible of these diseases in a high percentage of cases. The aim of 
this article is to present to the reader the estate of the art of the use of the new next 
generation sequencing technologies for the study of arrhythmogenic sudden cardiac deaths. 
We will discuss the different available technologies, and the different applications: 
Candidate gene resequencing. We will describe the interesting genes to be studied and the 
different strategies available for their enrichment and sequencing 
Whole exome resequencing. We will describe the application of this approach to those cases 
were we need to look for new genes. 
2. Inherited arrhythmogenic diseases 
There are various arrhythmogenic disorders, with different electrocardiographic patterns, 
which are not always present or are not evident in carriers of mutations implicated in the 
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pathology. In general these are diseases with low penetrance so the genetic study is of great 
importance in patients with personal or family history of sudden cardiac death. 
The term inherited arrhythmogenic diseases typically includes cardiac diseases caused by 
mutations in ion channels and ion channel-controlling proteins such as the long-QT syndrome 
(LQTS), the short QT syndrome (SQTS), the Brugada syndrome (BrS) and catecholaminergic 
polymorphic ventricular tachycardia (CPVT). Ion channels are integral membrane proteins 
that regulate the flow of ions across the cell membrane. They consist of multimeric units 
generally encoded by different genes. The ǂ subunit forms the pore and mediates ion current, 
while the ǃ subunits are regulatory. Defects in these channels due to mutations in genes that 
encode proteins, or mutations in proteins associated with these channels may lead to an 
electrical disturbance in the heart linked to the development of channelopathies. 
2.1 Long QT syndrome 
The Long QT Syndrome (LQTS) is characterized by prolongation of the QT interval on the 
electrocardiogram, which indicates ventricular repolarisation unusually long, due either to a 
decrease in the K+ flow of repolarisation or to a delayed entry of Na+ into the myocyte. 
The estimated incidence is between 1:2000 -1:5000 people (Hedley et al., 2009), and its 
penetrance  is variable, ranging from sub clinical phenotypes with a QT interval at the limit, 
without arrhythmias or syncope (Napolitano et al., 2005; Priori et al., 1999; Vicent et al., 
1992) to sudden cardiac death, being a major cause of sudden death in young people. To 
determine wheter the QT interval is prolonged the corrected QT interval (QTc) is used, 
which is calculated using the Bazzet formula QTc = QT / √ RR (Bazzet et al., 1920) Are 
considered abnormally prolonged QTc values when exceeding 440 ms in men and those 
over 460 ms in women (values corrected for heart rate). It is estimated that a patient with a 
QTc interval of 550 ms has a 63% higher risk of suffering a cardiac event that an individual 
with a value of QTc interval of 450 ms. (Zareba et al., 2008). 
The LQTS shows a congenital form of the disease in about 85% of cases and a sporadic form 
which corresponds to 15% [85]. There is also an acquired form of QT prolongation caused 
mainly by drugs, both cardiac (e.g. antiarrhythmics) and other medications (e.g. 
antidepressants) or derived from an electrolyte imbalance. The congenital form shows two 
basic patterns of inheritance, one autosomal dominant called Romano-Ward syndrome and 
another autosomal recessive known as Jervell Lange-Nielsen syndrome, which presents 
with congenital deafness. To date 12 genes have been described in the pathology. The most 
common are genes that encode K + channels, KCNQ1, KCNH2, which represent about 40-
55% and 35-45% of cases respectively,  and the SCN5A gene coding for Na + channels which 
represents a 2 - 8% of cases (Hedley et al., 2009). The involvement of each of these genes 
leads to defined clinical phenotypes, so KCNQ1 gene leads to LQTS type 1 (LQT1), KCNH2 
causes LQTS type 2 (LQT2) and SCN5A leads to LQTS3 (LQT3). 
2.2 Short QT syndrome 
The short QT syndrome (SQTS) has been recognized as a clinical entity characterized 
recently by a shortened QT interval that can lead to arrhythmias and sudden cardiac death 
(Gussak et al., 2000). Although there is no established consensus, it is accepted that a value 
between 320ms and 340 ms are considered short (although it could be considered normal 
340ms) if there is a history of cardiac symptoms such as syncope or aborted sudden death. 
Nevertheless, as in LQTS, the transition zone of normal QT intervals to pathological 
intervals is difficult to establish (Schimpf et al., 2007). 
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In SQTS, mutations in genes encoding K + channels: KCNH2, KCNJ2, and KCNQ1, cause a 
gain of function of these channels and give rise to SQTS1, SQTS2and SQTS3 respectively. 
However, mutations in genes encoding ǂ and ǃ2 subunits of the Cav1.2 channel, the 
CACNB2 and CACNA1C genes, cause loss of function of these channels and give rise to 
SQTS4 and SQTS5 phenotype respectively  (Hedley et al., 2009). 
2.3 Brugada syndrome 
Brugada Syndrome (BrS) is characterized by ST segment elevation in right precordial leads 
(V1-V3) of the electrocardiogram and can also be associated with an increase in PR interval 
and bundle branch block. Penetrance is also variable, and can trigger polymorphic ventricular 
tachycardia and / or ventricular fibrillation and sudden death. The distribution and incidence 
of this disease is difficult to determine because it is a syndrome recently described and because 
electrocardiographic manifestations are not always present. Campuzano et al. (2010) estimate a 
prevalence of approximately 35/100000 persons / year and they say that, although symptoms 
usually develop around the age of 40, sudden death can affect individuals of any age. They 
estimate sudden death affects 75% of the affected males, and between 20 and 50% of the 
affected people have a family history of sudden death. 
The dominant pattern of inheritance is autosomal dominant with expression probably age 
dependent and incomplete penetrance. Today we have described more than 100 mutations 
in 7 different genes that give rise to the 7 types of BrS. These genes encode proteins of both 
Na + channels and other ion channels. The mutations affect the proper development of 
phases 1 and 2 of the cardiac action potential (Hedley et al., 2009b). It is estimated that 20-
25% of BrS patients show mutations in the SCN5A gene (Schott et al., 1999), which also 
represents 5-10% of mutations found in cases of sudden cardiac death in adults and children 
(Hedley et al., 2009b) . 
2.4 Catecholaminergic polymorphic ventricular tachycardia 
Catecolaminergic polymorphic ventricular tachycardia (CPVT) occurs with a characteristic 
pattern of bidirectional or polymorphic tachycardia related to stress without structural 
cardiac abnormalities (Coumel et al., 1978). These clinical manifestations often occur during 
childhood and adolescence. 
The CPVT has two modes of inheritance: autosomal dominant and recessive. The autosomal 
dominant form is caused by mutations in the gene encoding the ryanodine receptor RyR2, 
which is a large protein that forms the calcium release channel in sarcoplasmic reticulum. 
The recessive form of the disease is caused by mutations in the cardiac isoform 
calciquestrina gene (CASQ2), which binds to the ryanodine receptor and participates in the 
control of excitation-contraction (Ylänen et al., 2010). The steps of the molecular 
pathogenesis of CPVT are not entirely clear, but Mutations of the two interacting proteins, 
RyR2 and CASQ2, seem to result in inadequately controlled Ca2+ bursts into the 
sarcoplasm, with concomitant risk of delayed afterdepolarizations and triggered 
arrhythmia. 
3. Genetic screening of arrhythmogenic diseases 
The importance of knowing the molecular substrate in patients with inherited cardiac 
channelopathies is recognized and highlighted in the guidelines for the prevention of SCD 
developed by the American Heart Association, the American College of Cardiology, and the 
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European Society of Cardiology (Zipes et al., 2006). Screening for mutations in genes that 
encode cardiac ion channels associated with LQTS, SQTS, BrS, and CPVT is primarily 
sought in clinically affected patients to tailor risk stratification and management and to 
further identify family members (Priori et al., 2002a, b, 2003). However, genetic analysis is 
not yet available at most clinical centres and it is still mainly performed in finite research 
laboratories. 
Our present understanding of human inherited arrhythmia diseases has become 
increasingly complex. Several clinical syndromes have been identified as human inherited 
arrhythmia diseases and at least 21 genes are known to cause these diseases. These genes 
and the associated syndromes are given in Table 1. Mutations associated with inherited 
arrhythmia syndromes occur in ion channel pore-forming proteins, associating subunit 
proteins and channel interacting proteins ,Ca2+ handling proteins, components of the ion 
cannel macromolecular complex, and regulatory pathways. Although most inherited 
arrhythmia syndromes are rare clinical findings, sometimes with just a single family 
described.  
Several studies have been published trying to determine the effectiveness of genetic 
screening (Bai et al., 2009; Kapplinget et al., 2009) in terms of efficiency and cost. Bay et al. 
(2009) showed that the current cost of genetic testing for inherited cardiac channelopathies is 
reasonable for those who have a conclusive diagnosis and that these patients should have 
priority access to genetic screening (Fuster et al., 2008) However, until now these studies 
were limited by two main drawbacks, the reduced effectiveness of the techniques of genetic 
determination employed and the high cost of the same. 
 
Gen Symbol Locus CPVT LQTS SQTS BrS 
A kinase  anchor protein (yotiao) 9 AKAP9 7q21-q22 x 
ankyrin 2 ANK2 4q25-q27 x 
calcium channel, voltage-dependent, L type, alpha 1C subunit CACNA1C 12p13.3 x x x 
calcium channel, voltage-dependent, beta 2 subunit CACNB2 10p12 x x 
calsequestrin 2 CASQ2 1p13.3-p11 x 
caveolin 3 CAV3 3p25 x 
glycerol-3-phosphate dehydrogenase 1-like GPD1L 3p22.3   x 
hyperpolarization activated cyclic nucleotide-gated potassium channel 4 HCN4 15q24.1 x 
potassium voltage-gated channel, Isk-related family, member 1 KCNE1 21q22.12 x 
potassium voltage-gated channel, Isk-related family, member 2 KCNE2 21q22.12 x 
potassium voltage-gated channel, Isk-related family, member 3 KCNE3 11q13.4 x 
potassium voltage-gated channel, subfamily H, member 2 KCNH2 7q36.1 x x 
potassium inwardly-rectifying channel, subfamily J, member 2 KCNJ2 17q24.3 x x 
potassium inwardly-rectifying channel, subfamily J, member 5 KCNJ5 11q24 x 
potassium voltage-gated channel, KQT-like subfamily, member 1 KCNQ1 11p15.5 x x 
ryanodine receptor 2 RYR2 1q43 x 
sodium channel, voltage-gated, type I, beta SCN1B 19q13,1 x 
sodium channel, voltage-gated, type III, beta SCN3B 11q23,3 x 
sodium channel, voltage-gated, type IV, beta SCN4B 11q23.3 x 
sodium channel, voltage-gated, type V, alpha subunit SCN5A 3p21 x x 
syntrophin, alpha 1 SNTA1 20q11.2   x     
Table 1. Genes related to arrhythmogenic sudden cardiac death 
Today, with the development of the next generation sequencing strategies, these two 
problems are being overcome, so that on one hand, we managed to sequence as many genes 
as we want, detecting both, genetic variants already described and new variants not yet 
known; and on the other hand, we have significantly reduced the cost of each genetic 
screening and we hope that this reduction will still see increased in the future days. 
The new next generation sequencing technologies are allowing us sequencing large number 
of DNA fragments or genes, using target resequencing strategies, in a fast, reliable and 
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effective way. The selection of the genes will depend on the researcher's own interests, so 
that in our case, we could focus on those genes previously described as involved in 
arrhythmogenic heart diseases or we can make the sequencing of all genes and search 
exome mutations also in genes that have not previously been associated with the pathology.  
If we consider the aforementioned 21 genes as candidate genes to be sequenced, It would 
involve the sequencing of approximately 400 exons, accounting around 120.000 base pairs of 
coding DNA. This work, in terms of time and cost of each analysis represents a major 
handicap for the routine work of many small laboratories dedicated to genetic diagnosis of 
these pathologies. An indicative example of this type of analysis is the Familion test for 
Long QT syndrome (Kapplinger et al., 2009), a  bidirectional DNA sequencing-based assay 
that comprises analysis of 73 polymerase chain reaction (PCR) amplicons to analyse the 3 
major LQTS-susceptibility genes (KCNQ1 [LQT1], KCNH2 [LQT2], SCN5A [LQT3]) along 
with 2 minor genes (KCNE1 [LQT5] and KCNE2 [LQT6]). Kapplinger et al (2009) evaluated 
the Familion Test in 2500 unrelated LQTS cases and they found 903 positive genetic tests 
describing 562 putative mutations absent in 2600 reference alleles.  They reported that 
despite the passage of 14 years since the first LQTS-causative mutations were discovered, 
still one-third of the mutations being discovered today are novel; therefore, this study is 
further evidence of the need for genetic screening strategies that allow us to detect both 
known mutations and new genetic variants, such as the sequencing. In addition, the study 
highlights the need for functional studies providing evidence on the possible pathogenicity 
for new genetic variants that are being described. Here we describe the implementation of a 
new research strategy using next generation sequencing,  that allows the simultaneous 
study of the sequence of all the genes described in relation to arrhythmogenic disorders at 
risk of sudden cardiac death (candidate gene approach), or the study of the complete 
sequence of the human exome (whole exome approach), searching for genetic variants both 
in genes previously associated with sudden cardiac death and in new genes whose 
involvement in the fatal event is currently unknown 
4. Next generation sequencing 
Capillary electrophoresis based in Sanger sequencing is the technology widely used for 
analyzing genes involves in different pathologies. However, over the past five years, Next 
Generation Sequencing (NGS) technologies have became a reliable tool for massive parallel 
sequencing, overcoming the limitations in throughput and speed of capillary electrophoresis 
(Shendure & Ji,  2008; Metzer, 2010; Glenn , 2011) .   
On this chapter we will focus on commercially available platforms: 454 (Roche), Illumina 
Genome Analyzer (Illumina Inc.), SOLiD and Ion Torrent (Life Technologies) (Table 2).  
The 454 Genome Sequencer (Roche) was the first NGS platform available (Margulies et al., 
2005). Small fragments of DNA are attached onto the surface of beads and amplified via 
emulsion PCR. Millions of beads are deposited onto a picotitre plate. Sequencing is 
performed in parallel by pyrosequencing, where the incorporation of a nucleotide by a DNA 
polymerase results in the release of a pyrophosphate, which initiates a series of downstream 
reactions that ultimately produce light by a luciferase. The light can be correlated with the 
nucleotide incorporated, because the nucleotides are added following a sequential order.  
The Illumina Genome Analyzer (Illumina Inc.) relies on bridge PCR on a glass slide  to 
amplify small fragments of DNA. In this approach, forward and reverse PCR primers are 
attached to a solid surface, and as a consequence, amplification products originating from 
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any single template molecule remain immobilized and clustered to a physical position on 
the array. Sequencing chemistry  is based on sequencing by synthesis with reversible 
terminators (Fedurco et al., 2006; Turcatti et al., 2008), where all fluorescently labeled four 
nucleotides are added simultaneously to the flow cell channels, along with the polymerase, 
for incorporation into the oligo-primed cluster fragments obtained after bridge PCR.  
The SOLiD system (Life Technologies) is based on sequencing by ligation and the use of 
two-base encoded probes (Valouev et al., 2008). A universal sequencing primer is 
hybridized to templates and a pool of fluorescently labelled octamer probes containing all 
possible combination of A, C, G and T at positions 1-5, interrogates the sequence of the 
unknown template on each bead. Only the probe homologous to the first five bases of the 
template will be ligated to the universal sequencing primer.  Up to ten cycles of ligation, 
detection and cleavage record the colour at every fifth position. Templates for sequencing 
are prepared via emulsion PCR.  
In the case of the Ion PGM Sequencer (Life Technologies), sequence data are obtained by 
directly sensing the ions produced by template-directed DNA polymerase synthesis using 
all natural nucleotides on the ion chip. The ion chip contains ion-sensitive, field-effect 
transistor-based sensors in 1.2 million wells, which allow parallel and simultaneous 
detection of independent sequencing reactions (Rothberg et al., 2011). As 454 and SOLiD, 
template preparation is performed by emulsion PCR. Unlike the other technologies where 
the throughput is determined by the equipment, the Ion PGM throughput is determined by 
the chip used for sequencing (Table 2) 
Very promising NGS approaches are the ones based on single molecule sequencing like 
Helicos Biosciences (Harris et al., 2008) and Pacific Biosciences (Eid et al., 2009), where 
sequencing is performing directly on the DNA, avoiding any amplification step. However, 
these platforms are not commercially available so they are only mentioned.  
 
 
Instrument Read length 
(bp) 
Maximum 
Throughput 
Run time 
454-GS Junior 400 50 Mb 10 h 
454-FLX+ 700 900 Mb 23 h 
Illumina-MiSeq 150+150 > 1 Gb 27 h 
Illumina-GAII 150+150 95 Gb 14 days 
Illumina-HiScanSQ 100+100 150 Gb 11 days 
Illumina-HiSeq1000 100+100 300 Gb 11 days 
Illumina-HiSeq2000 100+100 600 Gb 11 days 
SOLiD-5500 75+35 90 Gb 7 days 
SOLiD-5500xl 75+35 180 Gb 7 days 
Ion PGM – 314 chip 200 >10 Mb 2 h 
Ion PGM – 316 chip 200 >100 Mb 2 h 
Table 2. Comparison of NGS platforms.  
5. Target resequencing strategies 
For some applications, it would be not necessary to sequence the whole genome, but 
sequence specific region or regions. This is the case of the study of: i) a disease phenotype 
previously mapped to a specific region of the genome, ii) candidate genes involve in a 
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pathology or pathway, iii) whole exome. To reach these purposes it is necessary the 
combination of methods for targeted capture with massive parallel sequencing.  
Methods for capturing the regions of interest are commercially available, but it is important 
to remind that, due to this field is in continuous and rapid evolution, before designing any 
experiment it will be necessary to check for latest approaches, in order to choose the more 
cost-effective strategy for each project (Turner et al., 2009; Mamanova et al., 2010).  
Even considering the different capture strategies, the workflow for targeted resequencing 
for either candidate genes or exome sequencing is very similar. Genomic DNA is used to 
construct a library, which consists in small fragments of DNA flanqued by adaptors. 
Depending on the method used for capturing the regions of interest, the capture occurs 
before or after creating the library. Once the capture library is created, is clonally amplified 
followed by massive parallel sequencing.  
During the process of capturing and library preparation it is possible to barcoding samples.  
This process enables the user to pool multiple samples per sequencing run, taking 
advantage of the high-throughput of the NGS platforms.  
Capture strategies can be broadly grouped in two main groups, the first one is based on 
PCR, and the second one in the use of hybridization probes (Table 3).  
1. PCR approaches:  
When a specific region has been previously mapped, long-PCRs using high-fidelity 
polymerases are used to analyze large kilobase-sized contiguous intervals (Yeager et al., 
2008). 
Different strategies for amplified simultaneously hundreds of fragments of DNA have 
been developed over the last years. Access Array System (Fluidgm) uses a microfluidic 
chip with nanoliter scale chambers, where the simultaneous amplification of 48 
different fragments in 48 samples is performed. By incorporating the adaptor sequences 
into the primer design the amplicon product is ready to go directly into clonal 
amplification (Voelkerding et al., 2010).  
Microdroplet-PCR technology developed by RainDance involves the use of emulsion 
PCR in a microfluidic device, creating droplets of primers in oil solution. The primer 
droplets that are targeted to different regions of the genome merge with separate 
droplets that contain fragmented genomic DNA and PCR reagents. These mixed 
droplets are thermal cycled in a single tube. The encapsulation of microdroplet PCR 
reactions prevents possible primer pair interactions allowing an efficient simultaneous 
amplification of up to 20,000 targeted sequences (Tewhey et al., 2009). 
Illumina and Life Technologies have followed similar strategies for capture regions for 
MiSeq and Ion PGM Sequencer, respectively. Illumina has launched  the TrueSeq 
Custom Amplicon Kit for multiplex amplification of up to 384 amplicons per sample, 
and Life Technology has recently developed a multiplex PCR for amplified in a single 
tube up to 480 known as Ion AmpliSeq Cancer Panel.  Currently, only the cancer panel 
is available, but it has been announced by the company that custom panels will be early 
available.  
Halo Genomics has developed two different strategies based on amplification methods, 
Selector and HaloPlex. The first one, Selector Target Enrichment system is based on 
multiple displacement amplification. This strategy produces circular DNA that is 
amplified in a whole genome amplification reaction. The resulting high molecular DNA 
product is compatible with all next generation sequencing library preparation 
protocols. For achieving this, DNA sample is first fragmented using restriction 
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enzymes, secondly the probe library is added and the probes hybridize with the 
targeted fragments. Each probe is an oligonucleotide designed to hybridize to both ends 
of a targeted DNA restriction fragment, thereby guiding the targeted fragments to form 
circular DNA molecules. The circular molecules are closed by ligation and then 
amplified. Next step is library preparation (Johansson et al., 2010).   
In the case of HaloPlex technology, PCR products are ready for pooling and direct 
sequencing, it is not necessary to create the library after the capturing because the 
probes also contain a specific sequencing motif that is incorporated during the 
circularization. This motif allows the incorporation of specific adaptors and barcodes 
during the amplification.  Currently, this product is optimized for Illumina.  
2. Hybridization 
Other strategy is capture by hybridization of specific probes complementary of the 
regions of interest. The first hybridization approaches were based on-array capture 
(Albert et al., 2007; Hodges et al., 2007; Ng et al., 2009).  But to avoid the disadvantages 
of working with microarrays, currently methods are based in-solution capture. 
Fragment libraries are hybridized to biotinilated probes in solution and subsequently 
recovered with streptavidin-magnetic beads, amplified and sequence in the platform of 
choice (Gnirke et al., 2009; Bamshad., 2011).  
All the vendors (Agilent, Nimblegen, Illumina and Life Technologies) offer kits either 
predesigned for specific application such as exome sequencing, cancer, etc or custom 
panels to be designed for the user (Table 3). There are different kits for different sizes of 
the region of interest that go from less than 100kb to up 60 Mb.  
 
Approach Method Kitsa 
NGS – 
Compatibilityb 
PCR 
Long-PCR 1 1, 2, 3, 4 
Access Array System (Fluidigm) 1 1, 2, 3, 4 
Microdroplet PCR (Raindance) 1, 2 1, 2, 3, 4 
AmpliSeq technology  
(Life Technologies) 
2c 4 
TrueSeq Amplicon Kit (Illumina) 1 2 
HaloPlex (Halo Genomics) 1 2 
Selector (Halo Genomics) 1, 2 1, 2, 3, 4 
In-solution 
hybridization 
SureSelect (Agilent) 1, 3 2, 3 
SeqCap EZ (Nimblegen) 1, 3 1, 2, 3 
TrueSeq Enrichment Kit (Illumina) 1, 3 2 
TargetSeq (Life Technologies) 1, 3 3, 4 
a Custom (1), specific gene panel (ej. cancer panel) (2), exome panel (3) 
b 454 (1), Illumina (2), SOLiD (3), Ion PGM Sequencer (4). 
c  Custom early available 
Table 3. Capture methods for targeted resequencing.  
5.1 Candidate gene resequencing 
In dealing with arrhythmogenic diseases at risk of sudden cardiac death, we can analyze 
those genes previously associated with the pathologies that explain a high percentage of 
cases, variable according to the pathology (Hedley et al., 2009ab; Kapplinget et al., 2009). 
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Therefore, as it was already used for SCD associated cardiomyoapties  (Meder et al., 2011), 
the strategy with the arrhythmogenic diseases could be to capture the 21 genes mentioned 
above in Table 1. As it is shown in table 3, there are a great variety of strategies available. In 
addition, all commercially available kits have developed tools for designing specific primers 
or probes to capture the regions of interest.   
For selecting both the capture method and the NGS platform many factors have to be 
evaluated: size of the region of interest, the coverage and accuracy needed, the number of 
samples and barcodes availability and DNA requirement. There is no an ideal method for all 
the situations. 
5.2 Whole exome resequencing 
The targeted resequencing of the subset of the genome that is protein coding is known as 
exome sequencing. This strategy is been a powerful approach for either identifying genes 
involve in Mendelian disorders or rare variants underlying the heritability of complex traits 
(Bamshad, 2011). Therefore, arrhythmogenic diseases such as the LQTS, the SQTS, the CPVT 
or the BrS, all genetic diseases with Mendelian inheritance, are appropriate candidates for 
this type of study. 
All the vendors of in–solution hybridization methods have developed commercial kits for 
capturing whole exome. (Agilent, Illumina, LifeTechnologies, NimbleGen) (Table 3). Due to 
the throughput needed for obtaining enough coverage for variant calling, the platforms of 
choice for this application are Illumina GAII or superior and SOLiD 5500.  
This approach has been successfully used since 2009 in at least 29 diseases, in which the 
genes involved in the disorders have been identified (Bamshad, 2011).  
6. Genetic variant versus mutation 
It should be kept in mind that this kind of genetic tests identifies the presence of a 
probable/possible arrythmogenic disease causing mutation for which the probability for 
pathogenesis and even the likelihood of sudden cardiac death is influenced by many factors, 
including rarity, conservation, topological location, co-segregation, functional studies, and 
so forth. According to Kapplinger et al. (2009), fewer than 25% of the previously published 
LQTS mutations have been characterized by heterologous expression studies to demonstrate 
the anticipated loss-of-function (LQT1 and LQT2) or gain-of-function (LQT3) conferred by 
the mutation. The rank of a new genetic variant detected in an afected individual as a 
pathogenic mutation must meet the following specifications: 
a. The variant must disrupt either the open reading frame (i.e., missense, nonsense, 
insertion/deletion, or frame shift mutations) or the splice site (poly-pyrimidine tract, 
splice acceptor or splice donor recognition sequences). Considering the acceptor splice 
site as the 3 intronic nucleotides preceding an exón (designated as IVS-1, -2, or -3) and 
the donor splice site as the first 5 intronic nucleotides after an exon (designated as 
IVS+1, +2, +3, +4, or +5) (Rogan et al., 2003). 
b. The variant must be absent in a representative cohort of healthy unrelated individuals 
with a minimum of 200 individuals and 400 alleles with a common population origin. 
c. The variant must have been absent in all published databases listing the common 
polymorphisms in the studied genes and previously published reports or compendia of 
rare control variants. 
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Many of the possible new genetic variants described, although they meet the requirements 
listed above, may not have any pathogenic effect and the only real way to check would be 
through functional studies that prove this effect. Due to the difficulty in performing such 
studies in many of the functional proteins involved,  during the last years several “in silico” 
tools have been created allowing us to infer the probability that a genetic variant is 
pathogenic or not. Unfortunately, different prediction algorithms use different information 
and each has its own strength and weakness. Since it has been suggested that investigators 
should use predictions from multiple algorithms instead of relying on a single one, Liu et al 
(2011) have developed dbNSFP (database for nonsynonymous SNPs functional predictions). 
It compiles prediction scores from four algorithms (SIFT, Polyphen2,LRT, and 
MutationTaster), along with a conservation score (PhyloP) and other related information, for 
every potential non synonymous variant in the human genome. 
7. Conclusion 
Despite the progress in knowledge of the mechanisms, risk factors, and management of 
SCD, it remains being a major public-health problem. One of the challenges is the accurate 
identification of the person at risk, especially in younger people where the sudden death is 
most of the times the first manifestation of the disease. Multimarker SCD risk scores 
including demographic, clinical and genetic variables should improve the identification of 
persons at risk (Adabag et al., 2010). 
Although there are other processes affecting the electrical cardiac systole, pathologies 
considered in this chapter are the familiar diseases with a clear genetic inheritance in which 
genetic diagnosis has a great relevance.  
Capturing strategies followed by NGS allowed us to accurately detect arrhythmogenic 
disease causing mutations in a fast and cost-efficient manner that will be suitable for daily 
clinical practice of genetic testing. Nevertheless, we cannot forget the need to use additional 
strategies proving their disease causality. 
Additional benefits of great value in these  genetically and phenotypically heterogeneous 
disease are: 1) the ability to detect both, known mutations and novel mutations, 2) the 
possibility of screening only selected gene exons or all exons in the human genome, and 
finally 3) the ability to detect individuals with multiple mutations. 
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